Middle East Botanical Drug Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends

Top Countries — Revenue

USD Million/Billion

Access the full forecast model.

Country-level data · Company profiles · Editable dataset · Analyst consultation included.

Middle East Botanical Drug Market Analysis — Presence

Geographical Analysis

Click countries to explore
Loading map…

Country Analysis

Middle East Botanical Drug Market Analysis 2026

Region / Country 2021 (A)2025 (A)2033 (P) CAGR
Middle East Botanical Drug Totalxxxxxxxxxxxx40%
Saudi Arabiaxxxxxxxxxxxxxxxx
Turkeyxxxxxxxxxxxx39.5%
UAExxxxxxxxxxxxxxxx
Egyptxxxxxxxxxxxx40.3%
Qatarxxxxxxxxxxxxxxxx
Rest of Middle Eastxxxxxxxxxxxx39%

A = Actual · E = Estimated · P = Projected · 🔒 Locked values require full access. Click headers to sort.

Unlock full regional dataset →

Segmentation Analysis

Source breakdown · Illustrative 2025 shares shown free · Full-period forecast in paid report.

Single-Plant Extracts Middle East Botanical Drug Market Analysis
XX
Single-Plant Extracts Market Size 2025
XX %
CAGR
Locked · Full data in paid report
Polyherbal Formulations Middle East Botanical Drug Market Analysis
XX
Polyherbal Formulations Market Size 2025
XX %
CAGR
Locked · Full data in paid report
Standardized Extracts Middle East Botanical Drug Market Analysis
XX
Standardized Extracts Market Size 2025
XX %
CAGR
Locked · Full data in paid report

Market size by (Illustrative, 2025)
Share distribution (2025)

Disclaimer: The charts and graphs are for illustrative purposes only and do not represent actual market values. To access accurate quantitative data, please request a paid report or request free sample.

To learn more about market share and segmentation, request the free sample pages.

Competitor Analysis

Competitive Landscape of the Botanical Drug Market

The competitive landscape of the botanical drug market is characterized by a range of players competing to gain market share through product innovation, strategic partnerships, and aggressive marketing efforts. Key players in the market include established medicines manufacturers, specialized botanical drug companies, and emerging start-ups aiming to disrupt the market with innovative solutions.

May 2022: In order to treat exercise-induced diarrhea in dogs, Jaguar Health, Inc. has finished its final regulatory filing for the conditional new animal medication approval of Canalevia. (Source: https://jaguarhealth.gcs-web.com/news-releases/news-release-details/jaguar-health-completes-final-regulatory-filing-conditional-new) February 2022 (Jaguar Health Inc. announced that Napo Therapeutics has received the European Medicines Agency's Small and Medium Enterprise classification.) (Source: https://jaguarhealth.gcs-web.com/news-releases/news-release-details/jaguar-health-announces-receipt-napo-therapeutics-small-and)
Click any bar or cell to request the full company profile
Top Companies (In no particular order)2022 (A)2023 (A)2024 (A)2025 (A)
Company 1••• ••• ••• •••
Company 2••• ••• ••• •••
Company 3••• ••• ••• •••
Company 4••• ••• ••• •••
Company 5••• ••• ••• •••

We Provide Regional Breakdown of this Companies and Company specific to any Country, Region, Product/ service as well. We cover market share analysis for publicly listed companies as well as privately held companies, subject to data availability.

Request company profile for validation →

Report Scope & Analysis

According to cognitive market research, the global botanical drug market size was estimated at USD 169.6 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 3.39 million in 2024 and will grow at a compound annual growth rate (CAGR) of 40.0% from 2024 to 2031..

  • The GCC Countries' botanical drug market is projected to witness growth at a CAGR of 40.8% during the forecast period, with a market size of USD 1.45 million in 2024. Botanical Drug sales flourish due to the presence of major market players.
  • The Egypt botanical drug market is projected to witness growth at a CAGR of 40.3% during the forecast period, with a market size of USD 0.36 million in 2024.
  • The South African botanical drug market is projected to witness growth at a CAGR of 41.0% during the forecast period, with a market size of USD 0.54 million in 2024. Botanical Drug sales flourish in South Africa due to technological advancements, increasing demand, and regulatory support.
  • The Turkey botanical drug market is projected to witness growth at a CAGR of 39.5% during the forecast period, with a market size of USD 0.29 million in 2024.
  • The Nigerian botanical drug market is projected to witness growth at a CAGR of 39.1% during the forecast period, with a market size of USD 0.36 million in 2024.
  • The Rest of the MEA botanical drug market is projected to witness growth at a CAGR of 39.0% during the forecast period, with a market size of USD 0.40 million in 2024.
Many Middle Eastern and African nations have long practiced using herbal and plant-based remedies as part of their traditions and cultures. This cultural acceptance drives the demand for herbal medications. Several native plants in the area have therapeutic qualities. The distinctive flora of nations like South Africa, Morocco, and Egypt encourages the creation of botanical medicines. The market is expanding as a result of consumers' increasing awareness of the advantages of natural and organic products, especially botanical medications.

Analyst Conclusion

Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.

The Middle East Botanical Drug Market Analysis is witnessing significant growth in the near future.

In 2023, the Single-Plant Extracts segment accounted for a notable share of the Middle East Botanical Drug Market Analysis.

Supriya Yadav
Supriya Yadav Verified Analyst
Research Analyst
LinkedIn Profile Book a free Consultation

Frequently Asked Questions

Middle East Botanical Drug Market Analysis market size and growth rate is provided in the report covering 2021-2025 historical and 2025-2033 forecast data.
Major factors including drivers, restraints, opportunities and challenges are analyzed with detailed insights.
Top manufacturers and others are profiled in the report.
Segments include Source, Form and additional sub-segments.
Regional analysis covers all major markets. The report identifies the dominant region and provides country-level data.
Sample pages can be obtained on demand from the website. 24/7 chat support and direct call services are available.

★ Reviews

Rate this report

Middle East Botanical Drug Market Analysis — Table of Contents

Disclaimer:
  • This is just a redacted sample pages of the actual deliverable report and only for representative purposes
  • Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
  • The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
  • Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
  • If applicable; On Request Volume Data will also be provided (at an Additional Cost).
Report Scope
SourceSingle-Plant Extracts, Polyherbal Formulations, Standardized Extracts
FormTablets, Capsules, Powder, Ointments, Others
ApplicationOncology, Dermatology, Chronic Disease Management, Others
List of CompetitorsJaguar Health, Inc., GW Pharmaceuticals plc, Medigene AG, Ahn-Gook Pharmaceutical Co., Ltd., Bayer AG, Devonian Health Group Inc., Dr. Willmar Schwabe GmbH and Co. KG, Tsumura, Schwabe, Tong Ren Tang

  • Chapter 1. Competitor Analysis (Subject to Data Availability (Private Players))

    • 1.1 Top Competitors Analysis
      • 1.1.1 Top Players Ranking 2024
      • 1.1.2 New Product Launch Analysis
    • 1.2 Company Profile (Data Subject to Availability) Sample Format
      • 1.2.1 Jaguar Health
        • 1.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.1.2 Business Overview
        • 1.2.1.3 R&D Investment (Subject to data availability)
        • 1.2.1.4 Financials (Subject to data availability)
        • 1.2.1.5 Product Types Specification
        • 1.2.1.6 Business Strategy
        • 1.2.1.7 Recent Developments
        • 1.2.1.8 Management Change
        • 1.2.1.9 S.W.O.T Analysis
      • 1.2.2 Inc.
        • 1.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.2.2 Business Overview
        • 1.2.2.3 R&D Investment (Subject to data availability)
        • 1.2.2.4 Financials (Subject to data availability)
        • 1.2.2.5 Product Types Specification
        • 1.2.2.6 Business Strategy
        • 1.2.2.7 Recent Developments
        • 1.2.2.8 Management Change
        • 1.2.2.9 S.W.O.T Analysis
      • 1.2.3 GW Pharmaceuticals plc
        • 1.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.3.2 Business Overview
        • 1.2.3.3 R&D Investment (Subject to data availability)
        • 1.2.3.4 Financials (Subject to data availability)
        • 1.2.3.5 Product Types Specification
        • 1.2.3.6 Business Strategy
        • 1.2.3.7 Recent Developments
        • 1.2.3.8 Management Change
        • 1.2.3.9 S.W.O.T Analysis
      • 1.2.4 Medigene AG
        • 1.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.4.2 Business Overview
        • 1.2.4.3 R&D Investment (Subject to data availability)
        • 1.2.4.4 Financials (Subject to data availability)
        • 1.2.4.5 Product Types Specification
        • 1.2.4.6 Business Strategy
        • 1.2.4.7 Recent Developments
        • 1.2.4.8 Management Change
        • 1.2.4.9 S.W.O.T Analysis
      • 1.2.5 Ahn-Gook Pharmaceutical Co.
        • 1.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.5.2 Business Overview
        • 1.2.5.3 R&D Investment (Subject to data availability)
        • 1.2.5.4 Financials (Subject to data availability)
        • 1.2.5.5 Product Types Specification
        • 1.2.5.6 Business Strategy
        • 1.2.5.7 Recent Developments
        • 1.2.5.8 Management Change
        • 1.2.5.9 S.W.O.T Analysis
      • 1.2.6 Ltd.
        • 1.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.6.2 Business Overview
        • 1.2.6.3 R&D Investment (Subject to data availability)
        • 1.2.6.4 Financials (Subject to data availability)
        • 1.2.6.5 Product Types Specification
        • 1.2.6.6 Business Strategy
        • 1.2.6.7 Recent Developments
        • 1.2.6.8 Management Change
        • 1.2.6.9 S.W.O.T Analysis
      • 1.2.7 Bayer AG
        • 1.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.7.2 Business Overview
        • 1.2.7.3 R&D Investment (Subject to data availability)
        • 1.2.7.4 Financials (Subject to data availability)
        • 1.2.7.5 Product Types Specification
        • 1.2.7.6 Business Strategy
        • 1.2.7.7 Recent Developments
        • 1.2.7.8 Management Change
        • 1.2.7.9 S.W.O.T Analysis
      • 1.2.8 Devonian Health Group Inc.
        • 1.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.8.2 Business Overview
        • 1.2.8.3 R&D Investment (Subject to data availability)
        • 1.2.8.4 Financials (Subject to data availability)
        • 1.2.8.5 Product Types Specification
        • 1.2.8.6 Business Strategy
        • 1.2.8.7 Recent Developments
        • 1.2.8.8 Management Change
        • 1.2.8.9 S.W.O.T Analysis
      • 1.2.9 Dr. Willmar Schwabe GmbH and Co. KG
        • 1.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.9.2 Business Overview
        • 1.2.9.3 R&D Investment (Subject to data availability)
        • 1.2.9.4 Financials (Subject to data availability)
        • 1.2.9.5 Product Types Specification
        • 1.2.9.6 Business Strategy
        • 1.2.9.7 Recent Developments
        • 1.2.9.8 Management Change
        • 1.2.9.9 S.W.O.T Analysis
      • 1.2.10 Tsumura
        • 1.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.10.2 Business Overview
        • 1.2.10.3 R&D Investment (Subject to data availability)
        • 1.2.10.4 Financials (Subject to data availability)
        • 1.2.10.5 Product Types Specification
        • 1.2.10.6 Business Strategy
        • 1.2.10.7 Recent Developments
        • 1.2.10.8 Management Change
        • 1.2.10.9 S.W.O.T Analysis
      • 1.2.11 Schwabe
        • 1.2.11.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.11.2 Business Overview
        • 1.2.11.3 R&D Investment (Subject to data availability)
        • 1.2.11.4 Financials (Subject to data availability)
        • 1.2.11.5 Product Types Specification
        • 1.2.11.6 Business Strategy
        • 1.2.11.7 Recent Developments
        • 1.2.11.8 Management Change
        • 1.2.11.9 S.W.O.T Analysis
      • 1.2.12 Tong Ren Tang
        • 1.2.12.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.12.2 Business Overview
        • 1.2.12.3 R&D Investment (Subject to data availability)
        • 1.2.12.4 Financials (Subject to data availability)
        • 1.2.12.5 Product Types Specification
        • 1.2.12.6 Business Strategy
        • 1.2.12.7 Recent Developments
        • 1.2.12.8 Management Change
        • 1.2.12.9 S.W.O.T Analysis

  • Chapter 2. Global Botanical Drug Market Analysis

    • 2.1 Global Botanical Drug Market Analysis
    • 2.2 Global Botanical Drug Market Analysis by Source
    • 2.3 Global Botanical Drug Market Analysis by Form
    • 2.4 Global Botanical Drug Market Analysis by Application

  • Chapter 3. Middle East Botanical Drug Market Analysis

    • 3.1 Middle East Botanical Drug Market Analysis
    • 3.2 Middle East Botanical Drug Market Analysis by Country
    • 3.3 Middle East Botanical Drug Market Analysis by Source
    • 3.4 Middle East Botanical Drug Market Analysis by Form
    • 3.5 Middle East Botanical Drug Market Analysis by Application
    • 3.6 Middle East Botanical Drug Market Analysis by Key Players

  • Chapter 4. Saudi Arabia Botanical Drug Market Analysis

    • 4.1 Saudi Arabia Botanical Drug Market Analysis
    • 4.2 Saudi Arabia Botanical Drug Market Analysis by Source
    • 4.3 Saudi Arabia Botanical Drug Market Analysis by Form
    • 4.4 Saudi Arabia Botanical Drug Market Analysis by Application
    • 4.5 Saudi Arabia Botanical Drug Market Analysis by Key Players

  • Chapter 5. Turkey Botanical Drug Market Analysis

    • 5.1 Turkey Botanical Drug Market Analysis
    • 5.2 Turkey Botanical Drug Market Analysis by Source
    • 5.3 Turkey Botanical Drug Market Analysis by Form
    • 5.4 Turkey Botanical Drug Market Analysis by Application
    • 5.5 Turkey Botanical Drug Market Analysis by Key Players

  • Chapter 6. UAE Botanical Drug Market Analysis

    • 6.1 UAE Botanical Drug Market Analysis
    • 6.2 UAE Botanical Drug Market Analysis by Source
    • 6.3 UAE Botanical Drug Market Analysis by Form
    • 6.4 UAE Botanical Drug Market Analysis by Application
    • 6.5 UAE Botanical Drug Market Analysis by Key Players

  • Chapter 7. Egypt Botanical Drug Market Analysis

    • 7.1 Egypt Botanical Drug Market Analysis
    • 7.2 Egypt Botanical Drug Market Analysis by Source
    • 7.3 Egypt Botanical Drug Market Analysis by Form
    • 7.4 Egypt Botanical Drug Market Analysis by Application
    • 7.5 Egypt Botanical Drug Market Analysis by Key Players

  • Chapter 8. Qatar Botanical Drug Market Analysis

    • 8.1 Qatar Botanical Drug Market Analysis
    • 8.2 Qatar Botanical Drug Market Analysis by Source
    • 8.3 Qatar Botanical Drug Market Analysis by Form
    • 8.4 Qatar Botanical Drug Market Analysis by Application
    • 8.5 Qatar Botanical Drug Market Analysis by Key Players

  • Chapter 9. Rest of Middle East Botanical Drug Market Analysis

    • 9.1 Rest of Middle East Botanical Drug Market Analysis
    • 9.2 Rest of Middle East Botanical Drug Market Analysis by Source
    • 9.3 Rest of Middle East Botanical Drug Market Analysis by Form
    • 9.4 Rest of Middle East Botanical Drug Market Analysis by Application
    • 9.5 Rest of Middle East Botanical Drug Market Analysis by Key Players

  • Chapter 10. Source Analysis

    • 10.1 Single-Plant Extracts
    • 10.2 Polyherbal Formulations
    • 10.3 Standardized Extracts

  • Chapter 11. Form Analysis

    • 11.1 Tablets
    • 11.2 Capsules
    • 11.3 Powder
    • 11.4 Ointments
    • 11.5 Others

  • Chapter 12. Application Analysis

    • 12.1 Oncology
    • 12.2 Dermatology
    • 12.3 Chronic Disease Management
    • 12.4 Others

  • Chapter 13. Qualitative Analysis (Subject to Data Availability)

    • 13.1 Market Drivers
    • 13.2 Market Restraints
    • 13.3 Market Trends
    • 13.4 Market Opportunity
    • 13.5 Technological Road Map (Subject to Data Availability)
    • 13.6 Product Life Cycle (Subject to Data Availability)
    • 13.7 Customer and Buyer Behavior Analysis
      • 13.7.1 Digital Engagement, Customer Experience & Relationship Analysis
      • 13.7.2 Customer Buying Behavior & Purchase Decision Analysis
      • 13.7.3 Vendor Selection, Supplier Preferences & Future Demand Trends
      • 13.7.4 Pricing, Affordability & Value Perception Analysis
      • 13.7.5 Customer Segmentation & Demand Pattern Analysis
    • 13.8 Industrial Chain Analysis (Subject to Data Availability)
      • 13.8.1 Industry Chain Analysis
      • 13.8.2 Manufacturing Cost Analysis
      • 13.8.3 Supply Side Analysis
        • 13.8.3.1 Raw Material Analysis
        • 13.8.3.2 Raw Material Procurement Analysis
        • 13.8.3.3 Raw Material Price Trend Analysis
    • 13.9 PESTEL Analysis
      • 13.9.1 Environmental Factors
      • 13.9.2 Legal Factors
      • 13.9.3 Technological Factors
      • 13.9.4 Economic Factors
      • 13.9.5 Political Factors
      • 13.9.6 Social Factors
    • 13.10 Porter’s Five Forces Analysis
      • 13.10.1 Degree of Competition
      • 13.10.2 Threat of Substitutes
      • 13.10.3 Threat of New Entrants
      • 13.10.4 Bargaining Power of Buyers
      • 13.10.5 Bargaining Power of Suppliers
    • 13.11 Patent Analysis (Subject to Data Availability)
    • 13.12 ESG Analysis
    • 13.13 Geopolitical Outlook
      • 13.13.1 Global Power Realignment & Strategic Alliances
      • 13.13.2 Geopolitical Risk Landscape & Conflict Hotspots
      • 13.13.3 International Trade Relations & Market Access Environment
      • 13.13.4 Regulatory & Policy Shifts Impacting Cross-Border Operations
      • 13.13.5 Supply Chain Resilience, Localization & Resource Nationalism
      • 13.13.6 Technology Sovereignty & Digital Geopolitics
      • 13.13.7 Strategic Implications for Investment, Growth & Market Entry
    • 13.14 AI & Market Transformation
      • 13.14.1 Competitive Landscape Disruption & Strategic Shifts
      • 13.14.2 AI-Driven Transformation of Industry Value Chain
      • 13.14.3 Evolution of Business Models & Revenue Streams
      • 13.14.4 AI-Driven Product, Service & Innovation Transformation
      • 13.14.5 Customer Behavior, AI Adoption & Future Market Evolution

  • Chapter 14. Research Findings

    • 14.1 Key Takeaways
    • 14.2 Analyst Point of View
    • 14.3 Assumptions and Acronyms

  • Chapter 15. Research Methodology and Sources

    • 15.1 Primary Data Collection
      • 15.1.1 Steps for Primary Data Collection
        • 15.1.1.1 Identification of KOL
      • 15.1.2 Backward Integration
      • 15.1.3 Forward Integration
      • 15.1.4 How Primary Research Help Us
      • 15.1.5 Modes of Primary Research
    • 15.2 Secondary Research
      • 15.2.1 How Secondary Research Help Us
      • 15.2.2 Sources of Secondary Research
    • 15.3 Data Validation
      • 15.3.1 Data Triangulation
    • 15.4 Data Representation

Athenaeum AI Dashboard

Research Framework · 70:30 Primary:Secondary

Our Proprietary Methodology

Cognitive Market Research and Consulting "The Full Truth" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the Middle East Botanical Drug Market Analysis Market analysis.

01

Primary Intelligence Gathering

Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.

02

Secondary Data Triangulation

Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.

03

Expert Validation Protocol

Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.

04

Athenaeum AI Processing

Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.

05

Editorial & QA Review

Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.

Data Assurance Metrics
Data Points Validated 10,400+
Expert Interviews 54
Countries Covered 39+
Company Profiles 22+
Forecast Accuracy (Historical) 94.2%
Analytical Coverage
Market Sizing Revenue Forecast CAGR Analysis Competitor Benchmarking SWOT Porter's Analysis PESTEL Value Chain ESG Analysis Tariff Impact Patent Mapping Tech Trends

To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.

Sources from the Pharma and Healthcare Industry

How We Serve You

The Three Pillars of End-to-End Market Research Services

We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the Middle East Botanical Drug Market Analysis market.

Service 01

Market Survey

B2B B2C

Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the middle east botanical drug market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.

What's Included
  • Buyer intent & sentiment analysis
  • Purchase cycle mapping
  • Price sensitivity research
  • Channel preference profiling
  • Competitive perception study
Most Requested
Service 02

Customized Market Data & Reports

Custom Ready Report

Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.

What's Included
  • Ready syndicate report
  • Custom data scope & segmentation
  • Excel quantitative models
  • Board-ready PPT with key findings
  • Secure cloud portal access
Service 03

Strategic Consultation

With Survey With Report

Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.

What's Included
  • Dedicated analyst assigned to you
  • Live walkthrough of findings
  • Strategic Q&A sessions
  • Go-to-market recommendations
  • NDA-protected engagement

Customize This Report

Tell us the specific segments, regions, or companies you need — and we will tailor the deliverable to your requirements.